Dayi Hu is the President of the Chinese Society of Cardiology (CSC), President of the China Committee of Cardio-Cerebral-Vascular Diseases of GSC, a past president of the Chinese College of Cardiovascular Physicians (CCCP), Chief of the Intervention Centre at Peking University People’s Hospital, Dean of Clinical Research Institute at Shanghai’s Fudan University and a member of The International Academy of Sciences for Europe and Asia(IASEA). Professor Dayi Hu is a member of the Board of Directors of the International Society of Cardiovascular Pharmacotheraphy (ISCP), the editor-in-chief of Chinese Journal of Cardiology, an international board member of Journal of Clinical Cardiology, Journal of the American College of Cardiology, European Heart Journal, Nature Cardiovascular Medicine and also many other national and international medical journals. Professor Hu has been the editor-in-chief or major translator of 50 professional books, three of which have been published in United States.

Research Interest :Cardiology, Cardiovascular Pharmacology, Cardio-Cerebral-Vascular Diseases

Dr Avanzas graduated in Medicine at Universidad de Navarra, Pamplona, Spain. He completed Senior House Officer posts and registrar training in Cardiology at Gregorio Marañón Hospital in Madrid, Spain. He took up a Spanish Heart Foundation Research Fellowship at Coronary Artery Research Unit, St. George´s Hospital Medical School in London and in 2002 he was appointed as Associate Research Investigator of the Cardiovascular Biology Research Centre at St. George´s Hospital in London. He was appointed as Consultant Cardiologist in Gregorio Marañón Hospital, Madrid, Spain and he also took up an Interventional Cardiology Fellowship in Hospital Universitario Central de Asturias, Oviedo, Spain. He is now senior Consultant in Invasive Cardiology in this Hospital. Dr Avanzas is author of more than 150 peer-reviewed indexed articles and invited contributions. He is also involved in teaching medical students. He is a frequent speaker at national and international meetings.

Research Interest: cardiac syndrome X and interventional cardiology, particularly percutaneous valve replacement

Dr. Heinz-Peter Schultheiss, Professor of Internal Medicine and Cardiology, is CEO of Institute for cardiac diagnostic and therapy (IKDT) Berlin, Germany since 2003. He was the chairman of the Working group “Inflammatory heart muscle diseases“ of the German Society of Cardiology, Chairman of the “Working Group on Myocardial and Pericardial Disease“ of the European Society of Cardiology, Member of the "Council on Cardiomyopathies“ of the International Society of Cardiology, Chairman of the Medical Society Berlin, Member of German Society for Internal Medicine, Member of European Society of Cardiology.

Research Interest: Cardiomyopathy,Cardiac diseases, Inflammatory Heart diseases

Dr. Fumitoshi Satoh, 1987 Graduated from Tohoku University School of Medicine, Qualified M.D. Resident of Internal Medicine, Furukawa City Hospital, Japan 1989 Chief Resident of Internal Medicine, Iwaki General Hospital, Japan 1992-1996 Graduate School of Medicine, Tohoku University 1996 Qualified M.D,Ph.D. 1996-1997 Internal Medicine, Takata Hospital, Iwate, Japan 1997-2000 Research fellow; Department of Metabolic Medicine, Hammersmith Hospital, Imperial College of London, UK (Professor S.R. Bloom) 2000-2001 Internal Medicine, Tohoku Kosai Hospital, Japan 2001- Assistant Professor; Division Nephrology,Endocrinology, and Vascular Medicine, Tohoku University Hospital (Professor Sadayoshi Ito) 2008-2009 Senior Assistant Professor; Division of Nephrology, Endocrinology, and Vascular Medicine, Tohoku University Hospital 2010- Associate Professor
Research Interest: Hypertension, Nephrology,Endocrinology and Vascular Medicine

Dr. Lai-Hua Xie received his PhD degree from Kyoto University in 1999. He worked as a Postdoctoral Researcher and Adjunct Assistant Professor in UCLA before he moved to New Jersey Medical School in 2008. He is currently a tenured Associate Professor at RutgersNJMS. Dr. Xie is an expert in studying ion channel function, Ca2+ dynamics, and mechanisms for cardiac arrhythmias and dysfunction. He has published more than 80 reserch papers in prestigious journals such as Nature, PNAS, and Circulation Research, etc. His publications have been cited for more than 4000 times. His research is currently supported by NIH R01 grants.

Dr. Shade Akande philosophy of Nursing is grounded in quality and excellence in nursing practice with specific interest in the field of Cardiomyopathy. She population of interest being the older adult with heart failure residing in Nursing Homes, in the community, and at Skilled Nursing Facilities. She wealth of knowledge, educational background both international and here in USA, coupled with evidence based research will equip me with delivering outstanding care with positive outcome. She research into the success of “NP led Clinic” that was presented at the International Nurse Practitioner Conference in Australia (2002) and at Mayo Clinic (2003) were stepping stone to demonstration of quality care which positively impact the institution and patient alike. She doctoral project focused on identification of patient factors that are associated with re-admission of older heart failure patients from skilled Nursing Facilities within 30 days at Stony Brook University, NY. The significant findings were presented at the 7th National DNP Conference in Nashville, TN in 2014 and also at Stony Brook University Nursing Research day 05/2015, International Academy Cardiology world Congress July 2015 at Vancouver Canada and at the European Society of Cardiology (ESC) May 2016 at Florence Italy. As PI and co-investigators in NIH funded and multi-center research, She engage in inquiry that may assist with evidence based practice. She has engaged in both didactic and clinical teaching to Nurse Practitioner students and as mentors to Doctoral of Nursing Practice (DNP) students. As a clinician, She has the expertise, leadership and motivation to successfully contribute to the mission and values of programs and the institution as a whole. She is aware of importance of frequent communication among the project leaders, interdisciplinary team with construction of realistic plan and timeline. She plan to consistently and continually deliver excellent and quality care to the population with increased productivity and positive outcome, to foster unity and dedication to excellence, fostering education and to embrace the concept of continuous performance improvement.

Mary Shibuya is an experienced native English medical editor/writer of 32 years living in Japan with a background in chemistry and allergy research at Mayo Clinic (Rochester, MN). For 23 years she was the language editor of the journal Internal Medicine, published by the Japanese Society of Internal Medicine. In addition to editing and preparing research articles for publication in international journals, she attended various medical/scientific congresses as Press (interviews, transcription, summarizing). She also enjoys lecturing on scientific medical writing in English to graduate schools and pharmaceutical companies. She strives to encourage ESL doctors/researchers to publish in English.

Research Interest

Allergy research,chemistry,scientific medical writing 

Doris A. Taylor, Ph.D., FACC, FAHA is the Director, Regenerative Medicine Research, and Director, Center for Cell and Organ Biotechnology at the Texas Heart Institute in Houston. She holds faculty appointments at Texas A&M and Rice University. Taylor earned her B.S. from Mississippi University for Women in Biology and Physical Sciences and her Ph.D. in Pharmacology from the University of Texas Southwestern Medical Center. During her post-doctoral studies at Albert Einstein College of Medicine, she first worked with regenerative medicine strategies, growing heart muscle cells in the laboratory and working on gene therapy projects. She frequently appears as an expert on stem cell therapy and cardiac repair in the media and in the scientific arena. From cells to organs, Dr. Taylor is leading international regenerative medicine research efforts creating cutting edge therapies for chronic disease and “building the future treatments of tomorrow – today” at the Texas Heart Institute.